Loading...

Life Sciences Recovery And Digitalization Investments Will Improve Future Efficiency

Published
23 Feb 25
Updated
26 Sep 25
AnalystConsensusTarget's Fair Value
€19.13
40.5% undervalued intrinsic discount
26 Sep
€11.38
Loading
1Y
-39.6%
7D
-4.5%

Author's Valuation

€19.1340.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on26 Sep 25
Fair value Decreased 2.19%

Analysts have trimmed Azelis Group’s price target to €19.13, citing weaker Q2 earnings, a more conservative sector outlook, and increased market risk, partially offset by sustained strength in specialty testing. Analyst Commentary Reduced earnings estimates following a weaker-than-expected Q2 report.

Shared on05 Sep 25

Analysts have trimmed their earnings estimates and near-term growth outlook for Azelis Group amid sector challenges and softer fundamentals, resulting in a stable consensus price target of €19.56. Analyst Commentary Reduced earnings estimates following a weaker-than-expected Q2 report.

Shared on01 May 25
Fair value Decreased 21%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 1.31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.67%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 20%

AnalystConsensusTarget has increased revenue growth from 5.8% to 6.4%.